Search
prasinezumab
Contraindications:
- of no benefit for early Parkinson's disease [1]
* antibody at center of scientific miscoduct investigation
- papers cited on the web site of its developer, Prothena, are full of manipulated images [2]
Mechanism of action:
- monoclonal antibody that targets alpha-synuclein aggregates [1]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
neurologic agent
References
- Pagano G et al.
Trial of prasinezumab in early-stage Parkinson's disease.
N Engl J Med 2022 Aug 4;387:421.
PMID: 35921451
https://www.nejm.org/doi/10.1056/NEJMoa2202867
- Whone A.
Monoclonal antibody therapy in Parkinson's disease - The end?
N Engl J Med 2022 Aug 4;387:466.
PMID: 35921458
https://www.nejm.org/doi/10.1056/NEJMe2207681
- Pillar C
Picture imperfect. Scores of papers by Eliezer Masliah, prominent neuroscientist
and top NIH official, fall under suspicion.
Science Sept 26, 2024
https://www.science.org/content/article/research-misconduct-finding-neuroscientist-eliezer-masliah-papers-under-suspicion